Ozuriftamab vedotin clinical trials
Also written BA3021.
How each study uses ozuriftamab vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ozuriftamab vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Often tested with
Tested in the same studies.
Mecbotamab vedotin (1) · Vodudeutentan sodium (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ozuriftamab vedotin.
- Dec 2026Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerPhase 2 · Canadian Cancer Trials Group
Studies
Open first, then newest update. How each study uses ozuriftamab vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT04918186Written as BA3021How we know
- A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2BioAtla, Inc.NCT05271604Written as Ozuriftamab VedotinHow we know
- CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)CompletedPhase 1/2BioAtla, Inc.NCT03504488Written as CAB-ROR2-ADCHow we know
Codes
What other systems call ozuriftamab vedotin · ClinicalTrials.gg INT016127
- UNII (FDA) BPM6YN0KLIOZURIFTAMAB VEDOTINOne source FDA
- NCI Thesaurus C155812Ozuriftamab VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BPM6YN0KLI | OZURIFTAMAB VEDOTIN | One source FDA |
| NCI Thesaurus | C155812 | Ozuriftamab Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.